EF Hutton Acquisition Co. I Reaffirms “Buy” Rating for VolitionRx (NYSEAMERICAN:VNRX)

EF Hutton Acquisition Co. I reaffirmed their buy rating on shares of VolitionRx (NYSEAMERICAN:VNRX – Get Rating) in a report published on Thursday, Benzinga reports. They currently have a $6.00 price objective on the medical research company’s stock.

Separately, Benchmark cut shares of VolitionRx from a buy rating to a hold rating in a research note on Wednesday, February 1st. They noted that the move was a valuation call.

VolitionRx Trading Up 3.5 %

VNRX opened at $1.78 on Thursday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.04 and a current ratio of 1.04. The stock has a market capitalization of $103.49 million, a price-to-earnings ratio of -3.12 and a beta of 1.73. VolitionRx has a twelve month low of $1.31 and a twelve month high of $3.30.

Insider Activity

In other VolitionRx news, insider Jacob Vincent Micallef purchased 25,000 shares of the stock in a transaction dated Monday, December 19th. The shares were bought at an average price of $2.30 per share, with a total value of $57,500.00. Following the completion of the transaction, the insider now directly owns 188,392 shares in the company, valued at approximately $433,301.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, insider Jacob Vincent Micallef bought 25,000 shares of the firm’s stock in a transaction that occurred on Monday, December 19th. The shares were acquired at an average price of $2.30 per share, with a total value of $57,500.00. Following the acquisition, the insider now owns 188,392 shares of the company’s stock, valued at approximately $433,301.60. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Guy Archibald Innes bought 234,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 22nd. The shares were purchased at an average cost of $1.75 per share, for a total transaction of $409,500.00. Following the acquisition, the director now directly owns 154,504 shares in the company, valued at approximately $270,382. The disclosure for this purchase can be found here. Insiders have acquired a total of 264,000 shares of company stock valued at $478,350 over the last quarter. Company insiders own 16.00% of the company’s stock.

Institutional Trading of VolitionRx

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Cerity Partners LLC purchased a new position in VolitionRx in the 4th quarter worth approximately $92,000. Lagoda Investment Management L.P. grew its stake in VolitionRx by 15.3% in the 4th quarter. Lagoda Investment Management L.P. now owns 3,755,045 shares of the medical research company’s stock worth $9,125,000 after buying an additional 498,300 shares in the last quarter. Creative Planning purchased a new position in VolitionRx in the 4th quarter worth approximately $32,000. Cowen Prime Advisors LLC grew its stake in VolitionRx by 83.2% in the 4th quarter. Cowen Prime Advisors LLC now owns 177,043 shares of the medical research company’s stock worth $430,000 after buying an additional 80,412 shares in the last quarter. Finally, Spectrum Asset Management Inc. NB CA purchased a new position in VolitionRx in the 4th quarter worth approximately $135,000. Institutional investors own 10.30% of the company’s stock.

About VolitionRx

(Get Rating)

VolitionRX Ltd. is a multi-national life sciences company, which engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluid. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.